International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation ≥6: A new predictor of hemorrhagic early death in acute promyelocytic leukemia

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Mitrovic, Mirjana ^a   Suvajdzic, Nada ^a,b   Bogdanovic, Andrija ^a,b   Kurtovic, Nada Kraguljac ^a   Sretenovic, Aleksandra ^a   Elezovic, Ivo ^a   Tomin, Dragica ^a  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Acute promyelocytic leukemia; ATRA; Hemorrhagic early death; ISTH DIC score

Indexed keywords

ANTHRACYCLINE; FIBRINOGEN; RETINOIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING TEST; CONTROLLED STUDY; DEATH; DIFFERENTIATION SYNDROME; DISSEMINATED INTRAVASCULAR CLOTTING; EARLY DEATH; ENDOCRANIAL BLEEDING; FEMALE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; INFECTION; INTERNATIONAL SOCIETY OF THROMBOSIS AND HEMOSTASIS SCORING SYSTEM FOR DISSEMINATED INTRAVASCULAR COAGULATION SCORE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTHROMBIN TIME; RETINOIC ACID SYNDROME; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE; MIDDLE AGED; MORTALITY;

ADULT; AGED; BLOOD COAGULATION TESTS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; YOUNG ADULT;

MLCS; MLOWN;

EID: 84880625846     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0478-y     Document Type: Article

References (20)

1. Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, et al. Risk adapted treatment of acute promyelocytic leukemia with all trans retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103:1237-43.
2. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood. 2009;113:1875-91.
3. Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, et al. AIDA (all-trans retinoic acid+idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood. 1996;88:1390-8.
4. Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25:1128-34.
5. Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118:1248-54.
6. Jacomo RH, Melo RA, Souto RF, de Mattos ER, de Oliveira CT, et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica. 2007;92:1431-2.
7. Serefhanoglu S, Buyukasik Y, Goker H, Sayinalp N, Haznedaroglu IC, et al. Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy. Leuk Res. 2010;34:317-9.
8. McClellan JS, Kohrt HE, Coutre SR, Gotlib JR, Majeti R, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica. 2012;97:133-6.
9. De la Serna J, Montesinos P, Vellenga E, Rayon C, Parody R, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111:3395-402.
10. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620-5.
11. Shaffer LG, Slovak ML, Campbell LJ. An international system for human cytogenetic nomenclature. Basel: Karger; 2009.
12. Van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease (Report of the BIOMED-1). Leukemia. 1999;13:1901-28.
13. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. ITS Classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.
14. Sanz MA, Montesinos P, Rayon C, Holowiecka A, de la Serna J, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115:5137-46.
15. Lo-Coco F. ED in APL: tip of the iceberg? Blood. 2011;118:1188-9.
16. Taylor FB, Toh CH, Hoots WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Toward definition, clinical and laboratory criteria and scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327-30.
17. Yanada M, Matsushita T, Asou N, Kishimoto Y, Tsuzuki M, et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol. 2007;78:213-9.
18. Kim DY, Lee JH, Lee JH, Kim SD, Lim SN, et al. Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia. Leuk Res. 2011;35:152-8.
19. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145:24-33.
20. Sanz MA, Montesinos P. Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb Res. 2010;125:S51-4.